Ningbo Menovo Pharmaceutical Co (SHSE:603538) Other Current Assets: ¥111 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
74 GF Score
Price ¥27.30
GF Value ¥17.42
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Other Current Assets?

Ningbo Menovo Pharmaceutical Co SHSE:603538 +0.74% 74 Other Current Assets is ¥111 Mil as of Jun. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 74/100 and a GF Value™ of ¥17.42 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Ningbo Menovo Pharmaceutical Co's other current assets for the quarter that ended in Jun. 2026 was ¥111 Mil.

Ningbo Menovo Pharmaceutical Co's quarterly other current assets increased from Dec. 2025 (¥102 Mil) to Mar. 2026 (¥120 Mil) but then declined from Mar. 2026 (¥120 Mil) to Jun. 2026 (¥111Mil).

Ningbo Menovo Pharmaceutical Co's annual other current assets increased from Dec. 2023 (¥62 Mil) to Dec. 2024 (¥96 Mil) increased from Dec. 2024 (¥96 Mil) to Dec. 2025 (¥102 Mil).


Ningbo Menovo Pharmaceutical Co Other Current Assets Related Terms


Ningbo Menovo Pharmaceutical Co Other Current Assets Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Other Current Assets Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.29 74.61 61.84 96.40 102.22

Ningbo Menovo Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.91 106.44 102.22 120.48 111.40
SHSE:603538
74GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of ¥111 Mil mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Other Current Assets of ¥111 Mil as of Jun. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Ningbo Menovo Pharmaceutical Co.
Is Ningbo Menovo Pharmaceutical Co's Other Current Assets too high?
Ningbo Menovo Pharmaceutical Co's current Other Current Assets is ¥111 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Other Current Assets compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Other Current Assets of ¥111 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Ningbo Menovo Pharmaceutical Co. Ningbo Menovo Pharmaceutical Co's current Other Current Assets is ¥111 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.42, compared to a current price of ¥27.30 — trading 56.7% above its estimated fair value. The current Other Current Assets is ¥111 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Other Current Assets is ¥111 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥27.30 is trading 56.7% above its estimated GF Value™ of ¥17.42. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Other Current Assets: ¥111 Mil
  • GF Value™: ¥17.42 vs. price of ¥27.30 (56.7% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
74GF Score

Get the complete analysis for SHSE:603538

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.30
Price
¥17.42
GF Value